Mwafy, S., elanwar, N., Eid, A. (2020). Mismatch repair status in Endometrioid type of Endometrial Carcinoma: association with clinicopathological parameters. International Journal of Cancer and Biomedical Research, 4(3), 209-215. doi: 10.21608/jcbr.2020.35282.1053
Shorouk Mwafy; noha elanwar; Asmaa Eid. "Mismatch repair status in Endometrioid type of Endometrial Carcinoma: association with clinicopathological parameters". International Journal of Cancer and Biomedical Research, 4, 3, 2020, 209-215. doi: 10.21608/jcbr.2020.35282.1053
Mwafy, S., elanwar, N., Eid, A. (2020). 'Mismatch repair status in Endometrioid type of Endometrial Carcinoma: association with clinicopathological parameters', International Journal of Cancer and Biomedical Research, 4(3), pp. 209-215. doi: 10.21608/jcbr.2020.35282.1053
Mwafy, S., elanwar, N., Eid, A. Mismatch repair status in Endometrioid type of Endometrial Carcinoma: association with clinicopathological parameters. International Journal of Cancer and Biomedical Research, 2020; 4(3): 209-215. doi: 10.21608/jcbr.2020.35282.1053
Mismatch repair status in Endometrioid type of Endometrial Carcinoma: association with clinicopathological parameters
1Pathology Department, Faculty of Medicine, Tanta university
2Pathology Department, Faculty of Medicine, Tanta university
Abstract
Introduction: Endometrial carcinoma [EC], particularly the most predominant endometrioid type [EEC] is a major contributor to cancer burden globally, and its molecular classification has gained much importance recently. Aim: This study aimed to determine the immunohistochemical expression of mismatch repair proteins 'MLH1 and MSH2' in relation to clinicopathologic parameters in EEC and to characterize clinicopathologic features of mismatch repair protein (MMRP) deficient EEC. Material and methods: The current work was carried out on 80 cases of EEC retrieved [with clinical data] from the Department of Pathology, Faculty of Medicine, Tanta University in the period from June 2018 to December 2019. H&E staining and immunohistochemical staining with MLH and MSH2 were done for each case. Results: 29 (36.3%) carcinomas showed abnormal MMRP expression (11 cases showed isolated MLH1 deficiency (37.93%), 10 cases showed isolated MSH2 deficiency (34.48%), and 8 cases (27.59) showed a combined loss of both proteins), whereas the remaining 51 (63.7%) of cases demonstrated normal MLH1/MSH2 immunoreactivity (MMRP intact). MLH1, MSH2 expression, and MMRP status were closely related to some clinicopathologic features (patient’s age, histopathological tumor grade, and tumor stage) with a statistically significant relation. Conclusions: A subset of endometrioid type EC demonstrates MMRP defect; the MMRP deficient EEC often displays adverse clinicopathological parameters as poorly differentiated or undifferentiated histology, an advanced stage with young age at presentation.
Top